In the British pharmaceutical industry, there were five private equity deals announced in Q3 2024, worth a total value of $3.3m, according to GlobalData’s Deals Database. The $3.3m investment by EOS Investment Management, Medical Incubator Japan, Robert Kopple and Scottish Enterprise in ILC Therapeutics was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in the UK increased by 154% in Q3 2024 compared with the previous quarter’s total of $1.3m and fell by 100% as compared to Q3 2023. Related deal volume decreased by 17% in Q3 2024 versus the previous quarter and was 58% lower than in Q3 2023.
The top-ranked financial advisors supporting these private equity deals in the UK in 9M 2024 were KPMG International Coop; BDO International; Brown, Gibbons, Lang & Company with 2, 1, 1 deals respectively.
The top-ranked legal advisors supporting these private equity deals in the UK in 9M 2024 were Cleary Gottlieb Steen & Hamilton; CMS Legal Services EEIG; Dechert with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.